Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation

Author(s): Carrai V, Donnini I, Mazzanti B, Alterini R, Amato M P, et al.


Objective:Recently autologous haematopoietic stem cell transplantation (AHSCT) has been introduced for the treatment of severe forms of multiple sclerosis (MS). As little data are available on bone marrow (BM) of MS patients undergoing AHSCT, we investigated the morphological and phenotypic characteristics of MS BM.

Methods:BM biopsies of 14 MS patients screened for AHSCT and 10 control patients were evaluated to assess cellularity, morphology, immunological profile and bone marrow microenvironment. Immunohistochemistry analysis was performed to evaluate the expression of CD3, CD4, CD8, CD20, CD68, CD45, MMP-9.

Results:8 out of 14 MS (57%) patients showed a reduction of age-related bone marrow cellularity, possibly due to previous immunosuppressive therapies. There were no differences in the T CD3+ lymphocyte expression rate amongst MS and the control patients, the CD4/CD8 ratio (2:1) was maintained as was the rate of B lymphocytes. We found an increased, although not significant, MMP-9 expression (9.2%) in the bone marrow of MS patients, when compared to the control patients (6.3%).

Conclusion:The BM of MS patients showed a reduced cellularity and CD45+ cells content in comparison to the controls. A slightly increased expression of MMP-9 was also shown, possibly confirming an involvement of this compartment in the pathogenesis of the disease.

Similar Articles

Stem cell transplantation in multiple sclerosis: current status and future prospects

Author(s): Martino G, Franklin RJ, Baron Van Evercooren A, Kerr DA; Stem Cells in Multiple Sclerosis (STEMS) Consensus Group

Progress and prospects: stem cells and neurological diseases

Author(s): Gögel S, Gubernator M, Minger SL

Isolation of amniotic stem cell lines with potential for therapy

Author(s): De Coppi P1, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, et al.

Mesenchymal and haematopoietic stem cells form a unique bone marrow niche

Author(s): Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, et al.

The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

Author(s): Auletta JJ, Bartholomew AM, Maziarz RT, Deans RJ, Miller RH, et al.

Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals

Author(s): Djouad F, Plence P, Bony C, Tropel P, Apparailly F, et al.

Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis

Author(s): Liang J, Zhang H, Hua B, Wang H, Wang J, et al.

Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis

Author(s): Riordan NH, Ichim TE, Min WP, Wang H, Solano F, et al.

Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy

Author(s): Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, et al.

Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis

Author(s): Darlington PJ, Boivin MN, Renoux C, François M, Galipeau J, et al.